ADAM19 Promotes EMT-Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma.
- 1Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- 2Department of Pathology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Abstract
Detection of circulating tumor cells (CTCs), particularly characterization of their epithelial-mesenchymal transition (EMT) phenotypes, may improve prognostic accuracy for malignancies. Identification of novel biomarkers for CTC classification may improve the characterization of tumor progression and provide potential therapeutic insights for renal cell carcinoma (RCC). Herein, we identified that a disintegrin and metalloproteinase domain-containing protein 19 (ADAM19) was associated with EMT phenotypes of CTCs. In vitro functional experiments, Western blotting, and RNA sequencing demonstrated that ADAM19 promoted RCC malignant progression and EMT-related changes and was associated with NOTCH and NF-κB signaling pathways. Our findings further suggested potential bidirectional association between ADAM19 and these signaling pathways. CTCs isolated from xenograft mouse models exhibited enhanced proliferative, migratory, and invasive abilities, accompanied by increased ADAM19 expression compared with parental tumor cells. Clinical CTC analysis further revealed that ADAM19-Low-CTCs were associated with unfavorable clinical outcomes in RCC patients. Notably, higher time-updated ADAM19-Low-CTC counts were identified as an independent risk factor for progression-free survival (HR = 1.243, 95% CI: 1.006-1.536).
Related
- BRIX1 Promotes Hepatocellular Carcinoma Progression via the MAPK/ERK Pathway and Serves as a Prognostic Biomarker
- Immune and Circulating Biomarkers in Hepatocellular Carcinoma: Prognostic and Predictive Relevance for Immunotherapy
- Circulating Soluble EGFR Correlates with Tumor Burden and Hepatic Reserve but Lacks Independent Prognostic Value in Hepatocellular Carcinoma: A Prospective Turkish Cohort.
- Radiomics-based machine learning models decipher heterogeneity of anoikis-related molecular subtypes for prognostic stratification in head and neck squamous cell carcinoma
- Short-Term Changes in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Related Circulating Biomarkers Following a Very-Low Calorie Ketogenic Diet (VLCKD): A Paired Longitudinal Analysis
BibTeX
@article{he2026adam19,
title = {{ADAM19 Promotes EMT-Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma.}},
author = {Minxin He and Mingrui Li and Yifei Ma and Zhenzhuo Chen and Lingyu Guo and Xiangyu Wang and Wenjing Wang and Tie Chong and Zhenlong Wang},
journal = {Cancer science},
year = {2026},
month = oct,
doi = {10.1111/cas.70571},
url = {https://europepmc.org/article/MED/42958621},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - ADAM19 Promotes EMT-Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma.
AU - Minxin He
AU - Mingrui Li
AU - Yifei Ma
AU - Zhenzhuo Chen
AU - Lingyu Guo
AU - Xiangyu Wang
AU - Wenjing Wang
AU - Tie Chong
AU - Zhenlong Wang
PY - 2026
DA - 2026/10/29
JO - Cancer science
DO - 10.1111/cas.70571
UR - https://europepmc.org/article/MED/42958621
AB - Detection of circulating tumor cells (CTCs), particularly characterization of their epithelial-mesenchymal transition (EMT) phenotypes, may improve prognostic accuracy for malignancies. Identification of novel biomarkers for CTC classification may improve the characterization of tumor progression and provide potential therapeutic insights for renal cell carcinoma (RCC). Herein, we identified that a disintegrin and metalloproteinase domain-containing protein 19 (ADAM19) was associated with EMT phenotypes of CTCs. In vitro functional experiments, Western blotting, and RNA sequencing demonstrated that ADAM19 promoted RCC malignant progression and EMT-related changes and was associated with NOTCH and NF-κB signaling pathways. Our findings further suggested potential bidirectional association between ADAM19 and these signaling pathways. CTCs isolated from xenograft mouse models exhibited enhanced proliferative, migratory, and invasive abilities, accompanied by increased ADAM19 expression compared with parental tumor cells. Clinical CTC analysis further revealed that ADAM19-Low-CTCs were associated with unfavorable clinical outcomes in RCC patients. Notably, higher time-updated ADAM19-Low-CTC counts were identified as an independent risk factor for progression-free survival (HR = 1.243, 95% CI: 1.006-1.536).
SN - 1347-9032
SN - 1349-7006
ER -